https://scholars.lib.ntu.edu.tw/handle/123456789/512306
標題: | Exploring the heterogeneity of effects of corticosteroids on acute respiratory distress syndrome: A systematic review and meta-analysis | 作者: | SHENG-YUAN RUAN HSIEN-HO LIN CHUN-TA HUANG PING-HUNG KUO HUEY-DONG WU CHONG-JEN YU |
公開日期: | 2014 | 出版社: | BioMed Central Ltd. | 卷: | 18 | 期: | 2 | 起(迄)頁: | R63 | 來源出版物: | Critical Care | 摘要: | Introduction: The effectiveness of corticosteroid therapy on the mortality of acute respiratory distress syndrome (ARDS) remains under debate. We aimed to explore the grounds for the inconsistent results in previous studies and update the evidence.Methods: We searched MEDLINE, Cochrane Central Register of Controlled Trials and Web of Science up to December 2013. Eligible studies included randomized clinical trials (RCTs) and cohort studies that reported mortality and that had corticosteroid nonusers for comparison. The effect of corticosteroids on ARDS mortality was assessed by relative risk (RR) and risk difference (RD) for ICU, hospital, and 60-day mortality using a random-effects model.Results: Eight RCTs and 10 cohort studies were included for analysis. In RCTs, corticosteroids had a possible but statistically insignificant effect on ICU mortality (RD, -0.28; 95% confidence interval (CI), -0.53 to -0.03 and RR, 0.55; 95% CI, 0.24 to 1.25) but no effect on 60-day mortality (RD, -0.01; 95% CI, -0.12 to 0.10 and RR, 0.97; 95% CI, 0.75 to 1.26). In cohort studies, corticosteroids had no effect on ICU mortality (RR, 1.05; 95% CI, 0.74 to 1.49) but non-significantly increased 60-day mortality (RR, 1.30; 95% CI, 0.96 to 1.78). In the subgroup analysis by ARDS etiology, corticosteroids significantly increased mortality in influenza-related ARDS (three cohort studies, RR, 2.45, 95% CI, 1.40 to 4.27).Conclusions: The effects of corticosteroids on the mortality of ARDS differed by duration of outcome measures and etiologies. Corticosteroids did not improve longer-term outcomes and may cause harm in certain subgroups. Current data do not support routine use of corticosteroids in ARDS. More clinical trials are needed to specify the favorable and unfavorable subgroups for corticosteroid therapy. ? 2014 Ruan et al.; licensee BioMed Central Ltd. |
URI: | https://www.scopus.com/inward/record.uri?eid=2-s2.0-84899925827&doi=10.1186%2fcc13819&partnerID=40&md5=5277a184461d0de99f55cc4382e8af09 https://scholars.lib.ntu.edu.tw/handle/123456789/512306 |
ISSN: | 1364-8535 | DOI: | 10.1186/cc13819 | SDG/關鍵字: | corticosteroid; corticosteroid; adult respiratory distress syndrome; article; attributable risk; cohort analysis; corticosteroid therapy; exploratory research; human; infection risk; intensive care; meta analysis; mortality; outcome assessment; priority journal; randomized controlled trial (topic); risk factor; systematic review; controlled clinical trial (topic); procedures; Respiratory Distress Syndrome, Adult; treatment outcome; trends; Adrenal Cortex Hormones; Controlled Clinical Trials as Topic; Humans; Mortality; Respiratory Distress Syndrome, Adult; Treatment Outcome |
顯示於: | 醫學系 |
在 IR 系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。